Halfway Home Pets

Lets' get them the life they need

The separation of David Samadi from his parents and sister would teach him to be independent, and this has greatly influenced the person he is today. Just a teenager, David together with his brother Dan was forced to move to Belgium after the revolution in the year 1979. The separation from their parents was not easy but has helped shape them into strong individuals.

Even with the separation David did not give up and continued to study to achieve his dreams. His dream of becoming a doctor could have been shuttered, but with hard work and dedication Samadi had finished his first year at Stony Brook School of medicine and had received honors in just a short time. David Samadi’s journey as one of the most celebrated and innovative doctors had started, he later attended Montefiore Medical Center for his postgraduate degree and received training in Urology.

In 2002 in Paris France at Henri Mondor Hospital Creteil, under Professor’s Claude Abbou guidance, David finished a robotic radical prostatectomy residency. Dr. Samadi’s passion and dedication finally paid off, and he was appointed as the Chief of the division of Robotics in Urology sector at Mount Sinai. In 2010 Dr. David was also given an opportunity to serve as the Vice-chair of the department in the same hospital.

Dr. David Samadi’s work in the treatment of cancer has put him on the global platform since it is one of the severe conditions. His research and practice in cancer have not been limited, and he has worked on the treatments of kidney cancer, bladder cancer as well as prostate cancer. One of the most recognized projects David has worked on is robotic-assisted Laparoscopic Prostatectomy. This form of surgery is performed on men who have prostate cancer.

Dr. David Samadi has performed many prostate procedures and helped change the lives of many people, in his bid to improve the quality of life for more people around the world David established a platform that deals with robotic surgeries at Columbia Presbyterian Hospital and serves as the director of the robotic surgery in the urology department.

Dr. Samadi’s work in providing a solution suffering from cancer is exceptional and commendable he aims at coming up with therapies that treat the conditions and ensuring his patients, boost their sexual function and eliminate any chances of future occurrences.

His work in the health sector is an excellent step in the right direction and helping people all over the world remove the risk of cancer.

Learn More: prostatecancer911.com/david-samadi/

Eric Lefkofsky is the CEO as well as co-founder of Tempus. This is company dealing with technology. It has built an operating system that can help in the fight against cancer. Eric Lefkofsky is a founding partner of Lightbank which is a venture fund that invests in disruptive technologies.Eric Lefkofsky is the co-founder of Groupon and its Chairman too. This is a global e-commerce platform. He is the founder of Uptake Technologies which is an analytics platform for some of the largest industries in the world. He is also behind Mediaocean which provides various integrated procurement technologies. Echo Global Logistics is another transportation as well as logistics outsourcing company driven by technology that is promoted by Eric Lefkofsky. Next is InnerWorkings that is a provider of a number of print as well as promotional solutions globally.

Tempus is a cancer fighting startup. It comes from Eric Lefkofsky, the Groupon founder. With Tempus, Eric Lefkofsky wants to give data to doctors at the University of Chicago so that they can treat breast cancer patients in a much better way.Chicago-based Tempus has just announced its partnership with the University of Chicago Medicine Thursday. As per this partnership, Tempus will be providing molecular sequencing and analysis. This will be provided to the UChicago’s breast cancer specialists. It will help the doctors to create highly personalized treatment plans for their breast cancer patients. Here data will be analyzed from nearly 1,000 breast cancer patients. This type of data analysis will help doctors as well as researchers to uncover patterns that will be able to predict the response of patients to treatment.

Over time, it is expected that this data will help in providing better treatment along with highly improved patient outcomes.The fact is that breast cancer is one of the most common cancers today. But still there is very little accessible data that is available on the millions of patients who are battling or have battled this disease. Hence too many physicians are being forced to make treatment decisions with no help coming in from highly specific genetic information. Tempus will help them to make better informed decisions.